4/18
09:37 am
immx
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States [Yahoo! Finance]
Medium
Report
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States [Yahoo! Finance]
4/18
09:32 am
immx
Immix Biopharma on Track to Dose NXC-201 Patients in United States
High
Report
Immix Biopharma on Track to Dose NXC-201 Patients in United States
4/15
09:36 am
immx
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Low
Report
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
3/20
09:54 am
immx
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial [Yahoo! Finance]
Low
Report
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial [Yahoo! Finance]
3/20
09:46 am
immx
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Low
Report
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
3/5
09:40 am
immx
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative [Yahoo! Finance]
Medium
Report
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative [Yahoo! Finance]
3/5
09:35 am
immx
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Medium
Report
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
2/21
09:43 am
immx
Immix Biopharma 12 Month Review Progress Update [Yahoo! Finance]
Low
Report
Immix Biopharma 12 Month Review Progress Update [Yahoo! Finance]
2/21
09:31 am
immx
Immix Biopharma 12 Month Review Progress Update
Low
Report
Immix Biopharma 12 Month Review Progress Update
2/8
04:45 pm
immx
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
Low
Report
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
2/7
09:37 am
immx
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
Low
Report
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
2/5
10:43 pm
immx
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock [Yahoo! Finance]
Medium
Report
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock [Yahoo! Finance]
2/5
10:30 pm
immx
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
Medium
Report
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
2/5
03:43 pm
immx
Immix Biopharma to Launch Underwritten Public Offering [MarketWatch]
Medium
Report
Immix Biopharma to Launch Underwritten Public Offering [MarketWatch]
2/5
03:22 pm
immx
Immix Biopharma Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
High
Report
Immix Biopharma Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
2/5
03:20 pm
immx
Immix Biopharma Announces Proposed Public Offering of Common Stock
High
Report
Immix Biopharma Announces Proposed Public Offering of Common Stock